Summary
CAR-T(uning) will assess the technical and commercial feasibility of an improved and broadly applicable chimeric antigen receptor T-cell (CAR-T) approach based on a novel implemented mechanism of action. There is an urgent need for more effective treatment strategies against cancer, which remains the leading cause of death worldwide. Immuno-oncology regimens such as, immune checkpoint blockade therapy (ICT) and CAR-T therapy emerged as powerful tools in cancer treatment, however, in the majority of patients these fail to achieve long-lasting therapy response. Further, they remain costly and applicable to a limited range of cancer types. Specifically, CAR-T therapy faces two unresolved challenges: 1) limited therapy persistence; 2) tumor-induced immunosuppression. Consequently, no CAR-T therapy against solid tumor cancers has reached the market. Prof. Gottfried Baier has uncovered that inhibition of orphan nuclear receptor NR2F6, a downstream target of T cell antigen receptor signaling intermediate PKCθ, overcomes these shortcomings in a two-fold manner: 1) increased therapy persistence to improve its long-lasting effects; 2) reduced immunosuppression at the tumor site to improve immune response. Within this ERC PoC, first we will technically validate this approach using in vivo mouse and ex vivo patient-derived tumor models. We will focus on NSCLC as first indication, as it is one of the most-difficult to treat solid cancers with high mortality rate and disease burden. Subsequently, commercial feasibility will be determined by verifying IP position and strategy, performing in-depth market and competitor analyses, and finally consolidating these into a business plan to establish the best path to commercialization. Successful commercialization of CAR-T(uning) would reduce the socioeconomic burden of NSCLC, extending and improving patient lives, and enable the development of long-lasting, (cost-)effective CAR-T therapies applicable to a greater range of cancer types.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101054365 |
| Start date: | 01-09-2022 |
| End date: | 29-02-2024 |
| Total budget - Public funding: | - 150 000,00 Euro |
Cordis data
Original description
CAR-T(uning) will assess the technical and commercial feasibility of an improved and broadly applicable chimeric antigen receptor T-cell (CAR-T) approach based on a novel implemented mechanism of action. There is an urgent need for more effective treatment strategies against cancer, which remains the leading cause of death worldwide. Immuno-oncology regimens such as, immune checkpoint blockade therapy (ICT) and CAR-T therapy emerged as powerful tools in cancer treatment, however, in the majority of patients these fail to achieve long-lasting therapy response. Further, they remain costly and applicable to a limited range of cancer types. Specifically, CAR-T therapy faces two unresolved challenges: 1) limited therapy persistence; 2) tumor-induced immunosuppression. Consequently, no CAR-T therapy against solid tumor cancers has reached the market. Prof. Gottfried Baier has uncovered that inhibition of orphan nuclear receptor NR2F6, a downstream target of T cell antigen receptor signaling intermediate PKCθ, overcomes these shortcomings in a two-fold manner: 1) increased therapy persistence to improve its long-lasting effects; 2) reduced immunosuppression at the tumor site to improve immune response. Within this ERC PoC, first we will technically validate this approach using in vivo mouse and ex vivo patient-derived tumor models. We will focus on NSCLC as first indication, as it is one of the most-difficult to treat solid cancers with high mortality rate and disease burden. Subsequently, commercial feasibility will be determined by verifying IP position and strategy, performing in-depth market and competitor analyses, and finally consolidating these into a business plan to establish the best path to commercialization. Successful commercialization of CAR-T(uning) would reduce the socioeconomic burden of NSCLC, extending and improving patient lives, and enable the development of long-lasting, (cost-)effective CAR-T therapies applicable to a greater range of cancer types.Status
SIGNEDCall topic
ERC-2022-POC1Update Date
09-02-2023
Images
No images available.
Geographical location(s)
Structured mapping
